111 Inc 1 ADR represents 2 Class Common stocks YI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if YI is a good fit for your portfolio.
News
-
111 Announces Appointment of New Auditor
-
111, Inc. to Participate in Fireside Chat with Water Tower Research on July 18, 2024
-
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
-
111, Inc. Announces First Quarter 2024 Unaudited Financial Results
-
111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow
Trading Information
- Previous Close Price
- $1.13
- Day Range
- $1.13–1.20
- 52-Week Range
- $0.97–3.19
- Bid/Ask
- $1.06 / $1.20
- Market Cap
- $101.94 Mil
- Volume/Avg
- 17,713 / 48,091
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People’s Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
- Sector
- Healthcare
- Industry
- Medical Distribution
- Stock Style Box
- —
- Total Number of Employees
- 1,520
- Website
- https://ir.111.com.cn
Valuation
|
Metric
|
YI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.05 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
YI
|
|---|---|
Quick Ratio | 0.44 |
Current Ratio | 1.08 |
Interest Coverage | −13.48 |
Quick Ratio
YI
Profitability
|
Metric
|
YI
|
|---|---|
Return on Assets (Normalized) | −5.35% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −18.90% |
Return on Assets
YI
Medical Distribution Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| McKesson Corp
MCK
| Kzbmzfhs | Cfzmcj | $77.8 Bil | |||
| Cencora Inc
COR
| Dtztmmcw | Bfxyqj | $44.8 Bil | |||
| Cardinal Health Inc
CAH
| Wlfycfmtr | Jlszjl | $24.0 Bil | |||
| Shanghai Pharmaceuticals Holding Co Ltd Class H
SHPMF
| — | Kflzpt | $8.9 Bil | |||
| Shanghai Pharmaceuticals Holding Co Ltd ADR repr Class H
SHPMY
| — | Chbbwj | $8.9 Bil | |||
| Sinopharm Group Co Ltd
SHTDF
| — | Vwgck | $7.4 Bil | |||
| Sinopharm Group Co Ltd ADR
SHTDY
| — | Bsfjgj | $7.4 Bil | |||
| Amplifon SpA Az nom Post Frazionamento
AMFPF
| — | Nmqrly | $7.2 Bil | |||
| Medipal Holdings Corp ADR
MAHLY
| — | Jln | $3.7 Bil | |||
| Medipal Holdings Corp
MEPDF
| — | Jjp | $3.7 Bil |